Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?

The purpose of this study was to investigate the relationship between the expression of stem-cell markers nestin and cluster of differentiation 146 with clinicopathological characteristics in breast cancer and to determine whether a prognostic impact of nestin and CD146 expression exists regarding o...

Full description

Saved in:
Bibliographic Details
Main Authors: Ekaterini Christina Tampaki, Athanasios Tampakis, Afroditi Nonni, Konstantinos Kontzoglou, Efstratios Patsouris, Gregory Kouraklis
Format: Article
Language:English
Published: SAGE Publishing 2017-02-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317691181
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850053349858082816
author Ekaterini Christina Tampaki
Athanasios Tampakis
Afroditi Nonni
Konstantinos Kontzoglou
Efstratios Patsouris
Gregory Kouraklis
author_facet Ekaterini Christina Tampaki
Athanasios Tampakis
Afroditi Nonni
Konstantinos Kontzoglou
Efstratios Patsouris
Gregory Kouraklis
author_sort Ekaterini Christina Tampaki
collection DOAJ
description The purpose of this study was to investigate the relationship between the expression of stem-cell markers nestin and cluster of differentiation 146 with clinicopathological characteristics in breast cancer and to determine whether a prognostic impact of nestin and CD146 expression exists regarding occurrence of disease relapse in breast cancer. A total of 141 patients who were histologically diagnosed with breast cancer and underwent radical operations from November 2006 to October 2013 in Laiko General Hospital, National and Kapodistrian University of Athens, were enrolled in the study. CD146 and nestin protein expression were evaluated using immunohistochemistry. Nestin expression was observed in 18.4% (26/141) of the cases, while CD146 expression was observed in 35.5% (50/141) of the cases. Nestin expression is significantly higher in younger patients with breast cancer. Nestin and CD146 expression were not correlated with the tumor size and the presence of lymph node metastasis. On the contrary, a significantly higher expression of nestin and CD146 was observed with triple-negative cancers (p < 0.0001 for both markers), low differentiated tumors (p = 0.021 for nestin and p = 0.008 for CD146), and increased Ki-67 expression (p = 0.007 for nestin and p < 0.0001 for CD146). The nestin-positive group of patients and the CD146–positive group of patients presented significantly higher rates of disease recurrence (log-rank test, p = 0.022 for nestin and p = 0.003 for CD146) with a distant metastasis, 30 months after the primary treatment. CD146 but not nestin, however, predicted independently (p = 0.047) disease recurrence. Nestin and CD146 are expressed in breast cancer cells with highly aggressive potency. They might contribute to disease relapse in breast cancer by activating the epithelial–mesenchymal transition pathway and assist tumor neovascularization.
format Article
id doaj-art-72b3c82b06164594bf890bfd2e43fb40
institution DOAJ
issn 1423-0380
language English
publishDate 2017-02-01
publisher SAGE Publishing
record_format Article
series Tumor Biology
spelling doaj-art-72b3c82b06164594bf890bfd2e43fb402025-08-20T02:52:34ZengSAGE PublishingTumor Biology1423-03802017-02-013910.1177/1010428317691181Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?Ekaterini Christina Tampaki0Athanasios Tampakis1Afroditi Nonni2Konstantinos Kontzoglou3Efstratios Patsouris4Gregory Kouraklis52nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, GreeceDepartment of Surgery, University Hospital of Basel, Basel, Switzerland1st Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece1st Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, GreeceThe purpose of this study was to investigate the relationship between the expression of stem-cell markers nestin and cluster of differentiation 146 with clinicopathological characteristics in breast cancer and to determine whether a prognostic impact of nestin and CD146 expression exists regarding occurrence of disease relapse in breast cancer. A total of 141 patients who were histologically diagnosed with breast cancer and underwent radical operations from November 2006 to October 2013 in Laiko General Hospital, National and Kapodistrian University of Athens, were enrolled in the study. CD146 and nestin protein expression were evaluated using immunohistochemistry. Nestin expression was observed in 18.4% (26/141) of the cases, while CD146 expression was observed in 35.5% (50/141) of the cases. Nestin expression is significantly higher in younger patients with breast cancer. Nestin and CD146 expression were not correlated with the tumor size and the presence of lymph node metastasis. On the contrary, a significantly higher expression of nestin and CD146 was observed with triple-negative cancers (p < 0.0001 for both markers), low differentiated tumors (p = 0.021 for nestin and p = 0.008 for CD146), and increased Ki-67 expression (p = 0.007 for nestin and p < 0.0001 for CD146). The nestin-positive group of patients and the CD146–positive group of patients presented significantly higher rates of disease recurrence (log-rank test, p = 0.022 for nestin and p = 0.003 for CD146) with a distant metastasis, 30 months after the primary treatment. CD146 but not nestin, however, predicted independently (p = 0.047) disease recurrence. Nestin and CD146 are expressed in breast cancer cells with highly aggressive potency. They might contribute to disease relapse in breast cancer by activating the epithelial–mesenchymal transition pathway and assist tumor neovascularization.https://doi.org/10.1177/1010428317691181
spellingShingle Ekaterini Christina Tampaki
Athanasios Tampakis
Afroditi Nonni
Konstantinos Kontzoglou
Efstratios Patsouris
Gregory Kouraklis
Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?
Tumor Biology
title Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?
title_full Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?
title_fullStr Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?
title_full_unstemmed Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?
title_short Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?
title_sort nestin and cluster of differentiation 146 expression in breast cancer predicting early recurrence by targeting metastasis
url https://doi.org/10.1177/1010428317691181
work_keys_str_mv AT ekaterinichristinatampaki nestinandclusterofdifferentiation146expressioninbreastcancerpredictingearlyrecurrencebytargetingmetastasis
AT athanasiostampakis nestinandclusterofdifferentiation146expressioninbreastcancerpredictingearlyrecurrencebytargetingmetastasis
AT afroditinonni nestinandclusterofdifferentiation146expressioninbreastcancerpredictingearlyrecurrencebytargetingmetastasis
AT konstantinoskontzoglou nestinandclusterofdifferentiation146expressioninbreastcancerpredictingearlyrecurrencebytargetingmetastasis
AT efstratiospatsouris nestinandclusterofdifferentiation146expressioninbreastcancerpredictingearlyrecurrencebytargetingmetastasis
AT gregorykouraklis nestinandclusterofdifferentiation146expressioninbreastcancerpredictingearlyrecurrencebytargetingmetastasis